Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Toshimitsu Yamaoka

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

Comparison of Thick-Section and High-Resolution Computed Tomograpy for Bronchoscopic Diagnosis of Solitary Pulmonary Nodules.

Japanese Journal of Lung Cancer

English

Related publications

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Journal of Thoracic Oncology

English

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology

English

Responses to Crizotinib Can Occur in C-Met Overexpressing Nonsmall Cell Lung Cancer After Developing EGFR-TKI Resistance

Cancer Biology and Therapy

English

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology

English

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Journal of Thoracic Oncology

English

Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

PLoS ONE

Multidisciplinary

2015

English

P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Journal of Thoracic Oncology

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

2020

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Toshimitsu Yamaoka

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Comparison of Thick-Section and High-Resolution Computed Tomograpy for Bronchoscopic Diagnosis of Solitary Pulmonary Nodules.

Related publications

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Responses to Crizotinib Can Occur in C-Met Overexpressing Nonsmall Cell Lung Cancer After Developing EGFR-TKI Resistance

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC